On December 31st, 2017, Artificial Intelligence in Medicine, Inc. (AIM) has been acquired by Inspirata Holdings, Inc. USA. This transition to the Inspirata family of companies marks the start of a new and exciting era for AIM.

Importantly, AIM remains intact all staff remain and all projects and customer support services will continue as before. AIM will continue to support all of our products including our industry leading E-Path automated cancer reporting system, the Abrevio automated cancer case abstracting system, TissueMetrix, CytoBase, Merlin, PCR-2, and all hosted applications for customers.

By joining Inspirata, AIM will share in a broader vision of informatics solutions for the cancer care and surveillance communities.  Inspirata’s mission is to develop and deliver innovative cancer diagnostic solutions to optimize patient outcomes—to have a global impact on the diagnosis and treatment of cancer by identifying the right treatment for the right patient at the right time. This requires linking and extracting discrete information from a broad set of medical information sources and documents. AIM’s expertise in artificial intelligence methods, natural language processing, and large-scale cancer surveillance is a perfect strategic fit in this area.

AIM will become a center of excellence in A.I. and NLP, and together with Inspirata’s other business units, we will be able to provide customers with a broader range of intelligent information management solutions that will empower clinicians to make a patient’s medical journey faster, more effective, and more informed, while simultaneously providing researchers with information that will accelerate discovery.